FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION
◀ CONDITIONSPEPPUDEX
GOAL

Body Composition

Body composition research encompasses fat-mass reduction, lean-mass preservation, and visceral-adipose-tissue (VAT) targeting. Incretin agonists (GLP-3, GLP-2, GLP-1) drive whole-body fat reduction via central appetite suppression. GHRH analogs (GH-axis reference) preferentially target visceral adipose without significant subcutaneous-fat change. Body composition is the highest-volume search cluster in the broader metabolic-medicine category.

COMPOUNDS RESEARCHED FOR THIS GOAL · 15

GLP-1 card
No. 001HP 240
GLP-1
GLP-2 card
No. 002HP 200
GLP-2
IPA / CJC-1295 card
No. 009HP 140
IPA / CJC-1295
5-AMINO-1MQ card
No. 015HP 150
5-AMINO-1MQ
IGF-1 LR3 card
No. 017HP 175
IGF-1 LR3
GLP-3 card
No. 028HP 180
GLP-3
LIRAGLUTIDE card
No. 029HP 150
LIRAGLUTIDE
SERMORELIN card
No. 030HP 110
SERMORELIN
IPAMORELIN card
No. 031HP 130
IPAMORELIN
CJC-1295 card
No. 032HP 135
CJC-1295
GHRP-2 card
No. 033HP 125
GHRP-2
GHRP-6 card
No. 034HP 125
GHRP-6
HEXARELIN card
No. 035HP 140
HEXARELIN
FRAG 176-191 card
No. 039HP 125
FRAG 176-191
TESOFENSINE card
No. 040HP 145
TESOFENSINE
© 2026 Peppu Studio LLC · For Laboratory Research Use Only